标题
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
作者
关键词
-
出版物
Cancers
Volume 15, Issue 3, Pages 703
出版商
MDPI AG
发表日期
2023-01-24
DOI
10.3390/cancers15030703
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
- (2022) Felipe Batalini et al. CLINICAL CANCER RESEARCH
- AKT mutant allele-specific activation dictates pharmacologic sensitivities
- (2022) Tripti Shrestha Bhattarai et al. Nature Communications
- Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer
- (2022) Zhizhu Zhang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
- (2022) Caterina Gianni et al. Frontiers in Oncology
- Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic
- (2021) Ayushi F Chauhan et al. Cancer Management and Research
- The Role of mTOR Signaling as a Therapeutic Target in Cancer
- (2021) Nadezhda V. Popova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
- (2021) Rosalin Mishra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
- (2021) Chao Dong et al. Frontiers in Pharmacology
- Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
- (2021) Beike Wang et al. ONCOGENE
- Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
- (2021) Huayi Li et al. Cancers
- Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
- (2021) Nicholas Turner et al. BREAST CANCER RESEARCH AND TREATMENT
- Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors
- (2021) Anna Thulin et al. Scientific Reports
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
- (2021) Khalid El Bairi et al. npj Breast Cancer
- PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
- (2021) E.E. Dumbrava et al. ESMO Open
- Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors
- (2020) S.J. Isakoff et al. ANNALS OF ONCOLOGY
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
- (2020) Robert H Jones et al. LANCET ONCOLOGY
- The evolutionary history of 2,658 cancers
- (2020) Moritz Gerstung et al. NATURE
- mTOR in Lung Neoplasms
- (2020) Ildiko Krencz et al. PATHOLOGY & ONCOLOGY RESEARCH
- Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
- (2020) Lillian M Smyth et al. CLINICAL CANCER RESEARCH
- Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
- (2020) Ningni Jiang et al. MOLECULAR BIOLOGY REPORTS
- Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
- (2020) Timothy A. Yap et al. Cancer Discovery
- Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer
- (2020) Deborah L. Toppmeyer et al. Cancer Medicine
- Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations
- (2020) Athanasios Mavratzas et al. Future Oncology
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
- (2019) Ariella B. Hanker et al. Cancer Discovery
- A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma
- (2019) Alain Patrick Algazi et al. Pigment Cell & Melanoma Research
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
- (2019) Tian Tian et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
- (2019) N C Turner et al. ANNALS OF ONCOLOGY
- Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
- (2019) Geoffrey I. Shapiro et al. INVESTIGATIONAL NEW DRUGS
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
- (2019) Meran Keshawa Ediriweera et al. SEMINARS IN CANCER BIOLOGY
- Class II PI3K Functions in Cell Biology and Disease
- (2019) Federico Gulluni et al. TRENDS IN CELL BIOLOGY
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
- (2019) Ali S. Alzahrani SEMINARS IN CANCER BIOLOGY
- Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
- (2019) Ying Zhang et al. Expert Opinion on Drug Metabolism & Toxicology
- mTOR: Role in cancer, metastasis and drug resistance
- (2019) Avaniyapuram Kannan Murugan SEMINARS IN CANCER BIOLOGY
- PTEN in Hereditary and Sporadic Cancer
- (2019) Joanne Ngeow et al. Cold Spring Harbor Perspectives in Medicine
- Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
- (2019) M Brandão et al. ANNALS OF ONCOLOGY
- Management of toxicity to isoform α-specific PI3K inhibitors
- (2019) S E Nunnery et al. ANNALS OF ONCOLOGY
- Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth
- (2019) Ouma Cisse et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PI3K Inhibitors in Breast Cancer Therapy
- (2019) Haley Ellis et al. Current Oncology Reports
- Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
- (2018) Jose Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
- (2018) Willemijne A M E Schrijver et al. JNCI-Journal of the National Cancer Institute
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
- (2018) Wenting Zheng et al. LEUKEMIA
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
- (2018) Jake S. O’Donnell et al. SEMINARS IN CANCER BIOLOGY
- Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
- (2018) Willemijne A M E Schrijver et al. JNCI-Journal of the National Cancer Institute
- Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease
- (2018) John E. Burke MOLECULAR CELL
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
- (2018) Alison M. Schram et al. BRITISH JOURNAL OF CANCER
- Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
- (2018) Sarah P Blagden et al. CLINICAL CANCER RESEARCH
- Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective
- (2018) Aimie E. Garces et al. JOURNAL OF MEDICINAL CHEMISTRY
- Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors
- (2018) N. Tsolakos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
- (2018) Y.-J. Bang et al. EUROPEAN JOURNAL OF CANCER
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Vps34 Kinase Domain Dynamics Regulate the Autophagic PI 3-Kinase Complex
- (2017) Goran Stjepanovic et al. MOLECULAR CELL
- Class III phosphatidylinositol-3-OH kinase controls epithelial integrity through endosomal LKB1 regulation
- (2017) Fergal O’Farrell et al. NATURE CELL BIOLOGY
- A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)
- (2016) M. Martín et al. ANNALS OF ONCOLOGY
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Phosphatidylinositol 3‐phosphates—at the interface between cell signalling and membrane traffic
- (2016) Andrea L Marat et al. EMBO JOURNAL
- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- (2016) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
- (2016) Dong Wang et al. GYNECOLOGIC ONCOLOGY
- Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer
- (2016) Noboru Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- The Enigma of Rapamycin Dosage
- (2016) S. Mukhopadhyay et al. MOLECULAR CANCER THERAPEUTICS
- Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment
- (2016) Lydia WT Cheung et al. PHARMACOGENOMICS
- Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes
- (2016) YINGQIU XIE et al. Oncology Letters
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer
- (2016) M Mego et al. Journal of Cancer
- Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
- (2016) Linda S. Steelman et al. Aging-US
- BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
- (2016) Maria-Carmela Speranza et al. Scientific Reports
- Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways
- (2015) Amrita Chatterjee et al. CANCER LETTERS
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Taselisib (GDC-0032), a Potent -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
- (2015) Z. S. Zumsteg et al. CLINICAL CANCER RESEARCH
- Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
- (2015) C. P. Hall et al. CLINICAL CANCER RESEARCH
- Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib
- (2015) P. N. Lara et al. CLINICAL CANCER RESEARCH
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
- (2015) Ana Bosch et al. Science Translational Medicine
- PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling
- (2015) Laura Braccini et al. Nature Communications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- INPP4B: the New Kid on the PI3K Block
- (2015) Irina U. Agoulnik et al. Oncotarget
- PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
- (2014) HaiXia Li et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
- (2014) M. Y. Konopleva et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Classes of phosphoinositide 3-kinases at a glance
- (2014) S. Jean et al. JOURNAL OF CELL SCIENCE
- Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
- (2014) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines
- (2014) M. Puglisi et al. LUNG CANCER
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
- (2014) Alberto Ocana et al. PLoS One
- ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition
- (2013) Mahmoud Toulany et al. CANCER BIOLOGY & THERAPY
- PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
- (2013) Carolyn D. Britten CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest
- (2013) Paige Yellen et al. CANCER LETTERS
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
- (2013) Chudi O. Ndubaku et al. JOURNAL OF MEDICINAL CHEMISTRY
- The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
- (2013) Jing Li et al. Journal of Translational Medicine
- Suppression of AKT Phosphorylation Restores Rapamycin-Based Synthetic Lethality in SMAD4-Defective Pancreatic Cancer Cells
- (2013) Onica Le Gendre et al. MOLECULAR CANCER RESEARCH
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
- (2013) M. J. Niederst et al. Science Signaling
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines
- (2012) Brigette B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models
- (2012) Xianhua Wu et al. Journal of Translational Medicine
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
- (2012) C. P. Carden et al. MOLECULAR CANCER THERAPEUTICS
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
- (2011) Paige Yellen et al. CELL CYCLE
- Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma
- (2011) D. Opel et al. CLINICAL CANCER RESEARCH
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth
- (2011) D. Gaglio et al. Molecular Systems Biology
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- (2010) Qing-Bai She et al. CANCER CELL
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- (2010) C. O'Brien et al. CLINICAL CANCER RESEARCH
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1a and HIF-2a target genes
- (2010) Sang Y Chun et al. Molecular Cancer
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis
- (2010) A Bender et al. ONCOGENE
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
- (2010) C. G. Fedele et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair
- (2010) A. Kumar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
- (2009) J. Yun et al. SCIENCE
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started